Abstract Analysis of mutational signatures can reveal underlying molecular mechanisms of
the processes that have imprinted the somatic mutations found in cancer genomes. Here, we …

Immunotherapy has emerged as an attractive option for patients with relapsed or refractory
high-risk neuroblastoma (HRNB). Neuroblastoma (NB), a sympathetic nervous system …

Background Intrinsic and extrinsic factors in the tumour microenvironment (TME) contribute
to therapeutic resistance. Here we demonstrate that transforming growth factor (TGF)-β1 …

Neuroblastoma (NB), a heterogenous pediatric tumor of the sympathetic nervous system, is
the most common and deadly extracranial solid malignancy diagnosed in infants. Numerous …

Despite their indisputable importance in neuroblastoma (NB) pathology, knowledge of the
bases of NB plasticity and heterogeneity remains incomplete. They may be rooted in …

Neuroblastoma is a pediatric solid tumor characterized by strong clinical heterogeneity.
Although clinical risk-defining genomic alterations exist in neuroblastomas, the mutational …

Early childhood tumours arise from transformed embryonic cells, which often carry large
copy number alterations (CNA). However, it remains unclear how CNAs contribute to …

Neuroblastoma (NB) is one of the most lethal childhood cancers due to its propensity to
become treatment resistant. By spatial map** of subclone geographies before and after …

Simple Summary Neuroblastoma (NB) presents with two patterns of disease: with or without
metastasis. Both types of disease presentation include tumors with high-risk (HR) features …

Osteosarcoma is the most common primary cancer of the bone, with a peak incidence in
children and young adults. Using multi-region whole-genome sequencing, we find that …